Company: BKYI
Filing Date: 2025-11-07
Form Type: 8-K
Source: 0001437749-25-033877
Chunk: 0

Company: BIO KEY INTERNATIONAL INC
Filing Date: 2025-11-07
Form: 8-K
Item: Item 3.01
Chunk 0
---
Item 3.01.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously reported, on May 9, 2025, BIO-key International, Inc. (the “ Company”) received notice from the staff of The Nasdaq Stock Market, LLC (“ Nasdaq”) stating that the Company did not satisfy the continued listing requirement to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “ Bid Price Rule”), as the Company’s closing bid price was less than $1.00 per share for the 30 consecutive business days prior the date of the Nasdaq notice.

On November 6, 2025, the Company received a letter from Nasdaq (the “ Letter”) stating that although the Company had not regained compliance with the Bid Price Rule, Nasdaq determined that the Company is eligible for an additional 180-day period, or until May 4, 2026, to regain compliance with the Bid Price Rule. In the Letter, Nasdaq stated that its determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the minimum bid price requirement, and (ii) the Company’s written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.

If at any time during this second 180-day compliance period, the closing bid price of the Company’s common stock is at least $1 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation of compliance to the Company, and this matter will be closed. If compliance cannot be demonstrated by May 4, 2026, Nasdaq will provide written notification that the common stock will be delisted. At that time, the Company would have an opportunity to appeal the delisting determination to a Nasdaq Listing Qualifications Panel. The Company intends to monitor the closing bid price of its common stock and if required to maintain the listing of its common stock on Nasdaq Capital Market, effect a reverse stock split during this second 180-day compliance period.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                              BIO-